These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 28841096)
21. Impact of enterococcus on immunocompetent and immunosuppressed patients with perforation of the small or large bowel. Kaffarnik MF; Urban M; Hopt UT; Utzolino S Technol Health Care; 2012; 20(1):37-48. PubMed ID: 22297712 [TBL] [Abstract][Full Text] [Related]
22. What every intensivist should know about the management of peritonitis in the intensive care unit. Waele JJ Rev Bras Ter Intensiva; 2018 Mar; 30(1):9-14. PubMed ID: 29742214 [No Abstract] [Full Text] [Related]
23. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823 [TBL] [Abstract][Full Text] [Related]
33. [Clinical and microbiological characteristics of complicated intra-abdominal infection in Colombia: a multicenter study]. Vallejo M; Cuesta DP; Flórez LE; Correa A; Llanos CE; Isaza B; Vanegas S; Osorio J; Casanova L; Villegas MV Rev Chilena Infectol; 2016 Jun; 33(3):261-7. PubMed ID: 27598273 [TBL] [Abstract][Full Text] [Related]
34. Bacterial profile and patterns of antimicrobial drug resistance in intra-abdominal infections: current experience in a teaching hospital. Shree N; Arora BS; Mohil RS; Kasana D; Biswal I Indian J Pathol Microbiol; 2013; 56(4):388-92. PubMed ID: 24441227 [TBL] [Abstract][Full Text] [Related]
35. [Interpretation of domestic and foreign guidelines on diagnosis and treatment of abdominal infection]. Wu XW; Ren JA Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Nov; 23(11):1023-1027. PubMed ID: 33212548 [TBL] [Abstract][Full Text] [Related]
36. Current strategies for the treatment of complicated intraabdominal infections. Skrupky LP; Tellor BR; Mazuski JE Expert Opin Pharmacother; 2013 Oct; 14(14):1933-47. PubMed ID: 23876130 [TBL] [Abstract][Full Text] [Related]
37. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. Nicolau DP Expert Opin Investig Drugs; 2015; 24(9):1261-73. PubMed ID: 26145447 [TBL] [Abstract][Full Text] [Related]
38. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: evidence for the recommendations. Mazuski JE; Sawyer RG; Nathens AB; DiPiro JT; Schein M; Kudsk KA; Yowler C; Surg Infect (Larchmt); 2002; 3(3):175-233. PubMed ID: 12542923 [TBL] [Abstract][Full Text] [Related]
39. A practice-based observational study identifying factors associated with the use of high-dose tigecycline in the treatment of secondary peritonitis in severely ill patients. Maseda E; Suárez-de-la-Rica A; Anillo V; Salgado P; Tamayo E; García-Bernedo CA; Ramasco F; Villagrán MJ; López-Tofiño A; Giménez MJ; Granizo JJ; Hernández-Gancedo C; Aguilar L; Gilsanz F Rev Esp Quimioter; 2015 Feb; 28(1):47-53. PubMed ID: 25690145 [TBL] [Abstract][Full Text] [Related]
40. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities. Bodmann KF; Heizmann WR; von Eiff C; Petrik C; Löschmann PA; Eckmann C Chemotherapy; 2012; 58(4):282-94. PubMed ID: 23052187 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]